Korea Institute of Science and Technology

Ewha University-Industry Collaboration Foundation

Neuroventi

Sejin Jeon

Sung-Jin Hong

Hyunsoo Park

Taejin Ahn

Yangsoo Jang

Jeongjin Kim

Hea-jin Kim

Wooyeon Shin

Sohyun Joo

Yuliia Steshenko

Tae Kyeong Kim

Chanyoung Shin

Goo Taeg Oh

Hye-Young Yun

The present invention relates to a method for treating autism spectrum disorder, a mouse for monitoring autism spectrum disorder, and a method for screening a candidate for preventing or treating autism spectrum disorder. Specifically, according to the present invention, the output signal (or excitation of population) of neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum may be suppressed by introducing a halorhodopsin protein into neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum and then irradiating light to induce hyperpolarization of the halorhodopsin protein. Thus, the present invention has the effect of preventing or treating autism.

Method for treatment of autism spectrum disorder, mouse for monitoring autism spectrum disorder, and method for screening candidate material for prevention or treatment of autism spectrum disorder

The present invention relates to a composition for preventing, improving, or treating fragile X syndrome, fragile X syndrome-related developmental disorders, autism spectrum disorder or schizophrenia, comprising rilmenidine, a rilmenidine metabolite, or a pharmaceutically acceptable salt thereof.

Composition comprising rilmenidine compound as active ingredient for treatment of fragile X syndrome or related developmental disability

The present invention pertains to: a marker composition for diagnosing atherosclerosis severity; a composition for diagnosing atherosclerosis severity; an atherosclerosis severity diagnosis kit including the composition; a method for screening substances for preventing or treating atherosclerosis; and a method for providing information about a diagnosis of atherosclerosis severity, wherein LGI3 expression or activity levels are used. According to the present invention, the severity of atherosclerosis can be diagnosed or predicted, and personalized medicine and predictive medicine can be practiced using such information. Moreover, the present invention can treat atherosclerosis without affecting other metabolic phenotypes by administering an LGI3 antagonist.

Marker for diagnosing atherosclerosis severity, and diagnostic method using same

Growing community of inventors

Seoul, South Korea

Sejin Jeon